One-Year Outcomes of Faricimab Treatment for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration.

Published in: Clinical ophthalmology (Auckland, N.Z.) (2023)

A clinically significant minority of aflibercept-resistant nAMD subjects may attain longer treatment intervals and improved outcomes at 12 months after switching to IVF when a treat-and-extend treatment protocol is utilized. IVF use may be considered whenever resistance to IVA is encountered in this patient population.

Keyphrases

age related macular degeneration
randomized controlled trial
type diabetes
pregnant women
metabolic syndrome
adipose tissue
skeletal muscle
combination therapy
case report
replacement therapy
glycemic control
pregnancy outcomes
smoking cessation